Calculating the odds of winning a drug war

If winning the drug war means removing all access to illegal drugs then the odds of victory are close to zero. Supply‑side enforcement in the U.S. is unreliable. It fails to reduce drug availability or overall rates of addiction. Drugs are too profitable, too easy to smuggle, and too easy and cheap to replace in the event of captured shipments or arrests of smugglers. Smugglers are also easy to replace.

Under prohibition drug scheduling and enforcement priorities are driven by law enforcement, not health agencies, and not by scientific evidence that might otherwise eliminate punitive, culturalized, racialized, and ineffective efforts criminalizing addiction or use of a drug. Addiction is a human health problem, not a military target.

Enormous social costs are associated with prohibition strategies. There is no reliable estimate of the number of drug war related deaths that have occurred since President Richard M. Nixon declared his war on drugs in 1971 because no country retains the statistics for fatalities related to drug wars.

Despite lacking certain vital statistics drug wars promote increases in state corruption as well as producing drug crimes that lead to bloody extra‑judicial killings. Community disruptions originate with crime syndicates fighting over drug territories while inflicting their self-made justice onto their syndicate members or other people who betray their trust. Drug enforcement funding in the U.S. that began in 1981 with $1 billion increased to roughly $10 billion in the mid‑1990s while cocaine and heroin remained widely available and cheaper than before.

Recent U.S. military involvement in Ecuador’s drug enforcement has escalated to become joint operations targeting alleged “narco‑terrorist” groups with lethal force. Ecuador’s newly elected 35-year-old president, Daniel Noboa, equates organized crime with terrorism to justify military solutions over policing or social policy. He approved a military approach by the U.S. as a way to counter drug cartels in his country.

After a 2025 election that was too close for his own comfort, President Noboa concluded his political future will be secured by being tough on crime. The U.S. attack on Ecuadorian drug smugglers represents a unique political opportunity. Using drugs as an excuse he has suspended civil liberties in key regions of Ecuador and hired U.S. mercenary Erik Prince as his security consultant. Among the suspended civil liberties are citizens’ rights involving warrantless home searches, militarization of domestic policing, freedom of movement and assembly, protections against arbitrary detention, judicial oversight of security operations, and the arbitrary labeling of local gangs as terrorist organizations. Ecuador has begun construction of a high‑security El Salvador-style prison that will one day enable mass detention of prisoners minus any due process of law.

Problems occur with attempts to wipe out cartels. The most likely result of a war on cartels is the ongoing creation of new cartels. New cartels will adapt to new circumstances. Syndicates will continue to survive by using more sophisticated and less detectable smuggling strategies. Any progress made in taking on Ecuador’s cartels or those of any other country will be fleeting. Where there is a drug demand there will be a supply.

If winning a drug war means creating a huge enforcement bureaucracy that fails to eliminate most illegal drug use while providing a steady job and lifetime benefits to its federal and state employees then their jobs and pensions become the victory rather than that of limiting crime. There are no other reliable incentives for prohibitionists to win a drug war. Despite a decades long enforcement strategy an estimated 1.5 million Americans still have continuing access to cocaine no matter what the government does to stop it. Drug enforcement devolves into an ineffective and endless stalemate.

Drug enforcement propaganda depicting drug war successes can overstate the success. The contraband displayed by Attorney General Pam Bondi in a 2025 news release is exceptional in its size and potency, however the odds the drug enforcement agents seen in AG Bondi’s video will ever again be involved in a bust as large or larger are basically zilch. Large scale busts are rare.

Public health approaches to drugs consistently outperform punitive ones because there is a health focus on reducing a person’s physical and mental demand for the drug. If a medical cure for addiction emerges within the next few years it will make current drug treatment facilities medically obsolete. Thirty-five cents of every dollar the U.S. spends on drug enforcement goes to drug treatment that can fail to fully suppress physical or mental cravings for a drug. The most effective drug treatments offer a legal and medically prescribed drug substitute for the addictive substance. There is evidence that psychedelics can help reduce drug cravings, but access to psychedelics is difficult for many people because the drugs are currently being listed and prohibited on Schedule 1 of the controlled substances list. The scheduling list continues to grow as more chemical variations of listed drugs are created or discovered.

Winning the U.S. government’s war on certain drugs means that many people are foregoing effective medical remedies simply because a few bad actors can’t handle their drugs and a host of politicians fails to understand drugs. If the same set of rules were applied to owning automobiles no one would be allowed to drive — think of the children. What remains is a largely ineffective drug war industrial complex coupled with an unwillingness to move forward by implementing better health measures and fewer Kafkaesque bureaucracies.

This entry was posted in Servetus. Bookmark the permalink.

4 Responses to Calculating the odds of winning a drug war

  1. Servetus says:

    Sara Carter is the new Drug Czarina (Director of ONDCP). She is a former journalist and Fox News contributor who has covered drug smuggling stories from Latin America and the Middle East. Carter was assigned the directorship of the ONDCP on January 6, 2026, and she is pushing religion as the way to win the drug war. She says she wants to make faith central to the strategy, as if it hasn’t been tried before:

    YouTube: Trump Administration Makes Faith Central in Strategy to Combat Illicit Drugs

  2. Servetus says:

    New opioid discovery DFNZ has effective pain relief but does not cause respiratory depression or tolerance:

    1-Apr-2026 — Researchers at the National Institutes of Health (NIH) have identified a novel, highly potent opioid that shows potential as a therapy for both pain and opioid use disorder … the team observed the new drug’s effect in laboratory animals. They showed that it has high pain-relieving effects without causing respiratory depression, tolerance or other indicators of potential for addiction in humans.

    “Opioid pain medications are essential for medical purposes, but can lead to addiction and overdose,” said Nora D. Volkow, M.D., director of NIH’s National Institute on Drug Abuse (NIDA). “Developing a highly effective pain medication without these drawbacks would have enormous public health benefits.”

    The team investigated formulations of an understudied class of synthetic opioid compounds, known as nitazenes. Nitazenes selectively engage mu-opioid receptors, primary targets for opioid drugs in the brain and peripheral nervous system. However, nitazenes had been shelved in the 1950s due to their excessive potency. The scientific team revisited this class of compounds with a focus on harnessing their selectivity for the mu opioid receptor and engineering new nitazenes with a safer pharmacological profile.

    “Our goal was to study the profile, or pharmacology, of these drugs,” said Michael Michaelides, Ph.D., senior author and NIDA investigator. “We wanted to decrease the potency and create a potential therapeutic. What we discovered exceeded our expectations.”

    That investigation revealed DFNZ, another opioid dubbed a “superagonist” for its extremely high efficacy at the mu opioid receptor. […]

    At preclinical therapeutic doses, DFNZ produced a moderate and sustained increase in brain oxygen rather than depressing respiration. Repeated doses of the drug did not result in tolerance, drug dependency, or meaningful withdrawal effects. Among 14 classic opioid withdrawal symptoms, the researchers only observed irritability, as measured by vocalization, when handling DFNZ-treated rats. […]

    While DFNZ increases slow-acting dopamine release in the brain’s reward circuitry, it does not trigger the rapid dopamine bursts associated with the formation of strong drug-cue associations, the conditioned responses that drive craving and relapse in addiction. […]

    The research team will pursue additional preclinical studies to support an application for regulatory approval to conduct studies of DFNZ in humans. They believe several patient populations may benefit from DFNZ, including those in surgical settings and with cancer-related or chronic pain who have a particularly high need for effective pain treatment. […]

    AAAS Public Science News Release: NIH researchers discover pain-relieving drug with minimal addictive properties — Positive safety profile of novel drug compound is surprise for class of synthetic opioids shelved years ago

    Nature: A µ-opioid receptor superagonist analgesic with minimal adverse effects

    Authors: Juan L. Gomez, Emilya N. Ventriglia, Zachary J. Frangos, Agnieszka Sulima, Michael J. Robertson, Michael D. Sacco, Reece C. Budinich, Ilinca M. Giosan, Tongzhen Xie, Oscar Solis, Anna E. Tischer, Jennifer M. Bossert, Kiera E. Caldwell, Hannah Bonbrest, Amelie Essmann, Zelai M. Garçon-Poca, Shinbe Choi, Michael R. Noya, Feonil Limiac, Ali Arce, Grant C. Glatfelter, Margaret Robinson, Li Chen, Angelina A. Mullarkey, Dain R. Brademan, Garrett Enten, William Dunne, César Quiroz, Ingrid Schoenborn, Chae Bin Lee, Rana Rais, Daniel P. Holt, Robert F. Dannals, Lei Shi, Ruth Hüttenhain, Sergi Ferré, Eugene Kiyatkin, Jordi Bonaventura, Yavin Shaham, Venetia Zachariou, Michael H. Baumann, Georgios Skiniotis, Kenner C. Rice & Michael Michaelides.

  3. Servetus says:

    Psilocybin is found to be an effective treatment for obsessive compulsive disorder (OCD):

    Current treatments for obsessive–compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed. […]

    Psilocybin was generally well-tolerated, with no serious adverse events, or psychotic symptoms, and no significant changes in suicide severity scores. Psilocybin but not placebo significantly reduced YBOCS scores. At the end of 8-week treatment, after participants had received at least four high doses of psilocybin, 73.3% were responders (>35% reduction in YBOCS scores), with 40% in remission. These effects diminished but remained substantial at 6 months. Post hoc analysis of cumulative dosing correlated with YBOCS score reductions at the end of treatment. […]

    Journal of Psychopharmacology: A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder

    Authors: Francisco A. Moreno, Katja E. Allen, Katye E. Allen, Rajun Dunne, James I. Prickett, Brian Bayze, Christopher B. Wigand, and John J. B. Allen

  4. Servetus says:

    A study in Brazil ranked drugs according the frequency drugs were found in postmortems of homicide victims in different geographic areas:

    17-Apr-2026 — A Brazilian study based on postmortem toxicological analyses found that 53% of violent death victims had alcohol or drugs in their systems shortly after death. The study examined 3,577 cases in Belém (North), Recife (Northeast), Vitória (Southeast), and Curitiba (South), representing the four regions of the country. “The goal was to produce standardized and comparable data on the role of psychoactive substances in deaths from external causes in Brazil,” says Henrique Silva Bombana, a biomedical toxicologist, postdoctoral researcher at the University of São Paulo’s School of Pharmaceutical Sciences (FCF-USP), and the first author of the study. […]

    The profile of the victims reflects the most common face of violent mortality in the country: 89.7% were male, 56% were 30 years of age or older, and 67.3% died from homicide. This last figure is especially relevant when compared to the percentages of deaths from traffic accidents (14.7%) and suicides (9.2%). […]

    Of all the victims, 53% tested positive for at least one psychoactive substance. The most commonly detected substances were cocaine (29.6%), alcohol (27.7%), benzodiazepines (6.8%), and cannabis (2.2%). “The prevalence of cocaine was very significant in homicide cases, while alcohol was the most detected substance in traffic accident deaths. Benzodiazepines were prevalent in suicides,” reports Bombana. […]

    “The association between the substance and violent death in the case of homicide is very complicated, because we’re only looking at the victim, not the perpetrator. Still, it’s possible to attribute the high presence of cocaine not only to acute use of the substance but also to the social and economic context in which the illegal market operates – the environment of trafficking, selling, and buying that characterizes what we call structural violence,” Bombana argues.

    The presence of alcohol in traffic fatalities is a longstanding problem in the country. “The issue has been discussed for at least 30 years without a solution being found. The legislation is quite robust, but what may be lacking is greater control over the sale of alcohol. Some countries have much stricter and more restrictive rules for sales,” the researcher notes. […]

    When analyzing police records associated with homicide cases, the team found that approximately 85% of deaths were caused by gunshot wounds. “This occurred at a time when, through decrees and ordinances, the federal government at the time relaxed rules for purchasing and carrying firearms, increased limits on weapons and ammunition, expanded authorized categories, and reduced control and enforcement mechanisms – a context that helps explain the observed pattern of lethality,” Bombana emphasizes.

    The prominence of benzodiazepines in suicides raises questions about medication use, self-medication, and vulnerability. The researcher suggests a plausible hypothesis without attributing direct causality: “The use of these substances may end up serving as a trigger to transition from suicidal ideation to actual action.” […]

    Although he emphasizes that he is not a public policy specialist, Bombana argues that addressing the problem is more effective when centered on public health and harm reduction rather than repression. “Perhaps the criminalization policy, the so-called ‘war on drugs,’ isn’t the best option. Portugal decriminalized drug use and saw a decrease in the number of users, petty crimes, homicides, and overdoses. The differences between Portugal and Brazil are enormous, of course. Starting with the size of the territories and populations. Still, the Portuguese example suggests that a harm reduction policy may be the most promising path.” […]

    AAAS Public Science News Release: More than half of the victims of violent deaths in Brazil had consumed alcohol or drugs shortly before — postmortem analyses of 3,577 cases in four state capitals reveal a consistent association between psychoactive substances and homicides, accidents, and suicides, with distinct regional patterns

    Toxics: Prevalence of Psychoactive Substance Use and Violent Death: Toxicological and Geospatial Evidence from a Four-Metropolitan-Area Cross-Sectional Study in Brazil

    Authors: Henrique Silva Bombana,Vanderlei Carneiro da Silva, Ivan Dieb Miziara, Heráclito Barbosa Carvalho, Mauricio Yonamine, and Vilma Leyton.

Leave a Reply

Your email address will not be published. Required fields are marked *